Clik here to view.
Del. supremes uphold Fresenius bailout on Akorn buy
Delaware’s Supreme Court ruled last week to uphold a decision by the state’s Chancery Court that Fresenius (ETR:FRE) could walk away from its $4 billion merger with Akorn (NSDQ:AKRX). The initial deal...
View ArticleClik here to view.
Tidepool raises $6m to develop automated insulin delivery app
Tidepool said this week that it raised $6 million from JDRF and the Leona M. & Harry B. Helmsley Charitable Trust to support the development of Tidepool Loop – a hybrid, closed-loop automated...
View ArticleClik here to view.
Intersect ENT launches trial of drug-coated sinus balloon
Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon. The Menlo Park, Calif.-based company’s device is designed to deliver...
View ArticleClik here to view.
Investigators hit pause on trials following concerns over paclitaxel-coated...
A meta-analysis published in the Journal of the American Heart Association last week suggested that patients treated with paclitaxel-coated balloons and stents for peripheral artery disease could be at...
View ArticleClik here to view.
Diabetes tech execs talk patient-centric design, device development & trust
John Timberlake has been commercializing diabetes drugs and devices for 25 years. Over the course of his career, one theme has always stood out: if you want people to use your product, it has to be...
View ArticleClik here to view.
FDA approves Teva’s digital COPD, asthma inhaler
Teva (NYSE:TEVA) said this week that the FDA approved its ProAir Digihaler device – a digital inhaler that uses sensors to connect to a companion mobile app for people with asthma and chronic...
View ArticleClik here to view.
Acorda wins FDA nod for inhaled Parkinson’s therapy
Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of “off” episodes in people with Parkinson’s disease. The self-administered,...
View ArticleClik here to view.
Ocular Therapeutix lands $25m term loan
Ocular Therapeutix (NSDQ:OCUL) said today that it closed a refinancing of its existing debt by landing a $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan...
View ArticleClik here to view.
Researchers design ingestible sensor for controlled drug release
Image courtesy of the researchers Researchers from MIT, Brigham & Women’s Hospital and Draper have developed a Bluetooth-controlled ingestible capsule that can sense the temperature of its...
View ArticleClik here to view.
Report: Pharma companies kick off new year with price hikes
Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the...
View ArticleClik here to view.
Valeritas’ V-Go wins preferred status on Humana’s Medicare formularies
Valeritas (NSDQ:VLRX) said today that its V-Go insulin delivery device won preferred status on Humana’s Part D formularies. The Bridgewater, N.J.-based company’s device is designed for people with Type...
View ArticleClik here to view.
Results RNA recalls eye drops over undeclared colloidal silver
Results RNA said this week that it voluntarily recalled its Lubrisine eye drops following an FDA inspection that found the product was not manufactured with sterile practices. The company also said...
View ArticleClik here to view.
Frequency Therapeutics raises $42m for hearing regeneration drug
Frequency Therapeutics said today that it closed a $42 million Series B round to support the clinical development of its hearing regeneration drug, FX-322. The company is slated to publish top-line...
View ArticleClik here to view.
Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The...
View ArticleClik here to view.
Vital Therapies pulls the trigger on Immunic share swap
Vital Therapies (NSDQ:VTL) said today that it inked a deal to swap shares with Germany-based Immunic, transitioning its efforts to focus on Immunic’s pipeline of drugs for chronic inflammatory and...
View ArticleClik here to view.
ResMed closes $225m Propeller Health purchase
ResMed (NYSE:RMD) said yesterday that it completed its $225 million acquisition of Propeller Health and its digital medicine platform. Lead by CEO David Van Sickle, Propeller will continue to operate...
View ArticleClik here to view.
Decibel, Cocoon tackle drug delivery to the inner ear using silk
Decibel Therapeutics and Cocoon Biotech announced yesterday that the two companies plan to work together to research drug formulations optimized for transtympanic delivery to the ear. The collaboration...
View ArticleClik here to view.
Nobilis files IND for trial to study drug-device PTSD therapy
Nobilis Therapeutics said yesterday that it filed an investigational new drug application with the FDA to kick off a Phase IIb trial of its NBTX-001 drug-device PTSD therapy. The Portland, Ore.-based...
View ArticleClik here to view.
Sandoz, Pear launch digital therapy for opioid use disorder
Novartis (NYSE:NVS) division Sandoz and Pear Therapeutics this week kicked off the U.S. commercial launch of the first FDA-cleared prescription digital therapy for people with opioid use disorder. The...
View ArticleClik here to view.
Amgen touts lowered prices for Repatha delivery devices
Amgen (NSDQ:AMGN) said today that it lowered the list prices of the drug-delivery devices for its cholesterol drug, Repatha, to $5,850 per year. The Thousand Oaks, Calif.-based company touted the 60%...
View Article